United Therapeutics (United Therapeutics) FCF Margin % : 11.71% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. United Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $72 Mil. United Therapeutics's Revenue for the three months ended in Dec. 2023 was $615 Mil. Therefore, United Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 11.71%.

As of today, United Therapeutics's current FCF Yield % is 6.79%.

The historical rank and industry rank for United Therapeutics's FCF Margin % or its related term are showing as below:

UTHR' s FCF Margin % Range Over the Past 10 Years
Min: -20.04 Med: 30.22 Max: 46.95
Current: 32.12

During the past 13 years, the highest FCF Margin % of United Therapeutics was 46.95%. The lowest was -20.04%. And the median was 30.22%.

UTHR's FCF Margin % is ranked better than
94.68% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs UTHR: 32.12

United Therapeutics FCF Margin % Historical Data

The historical data trend for United Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics FCF Margin % Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-20.04

46.95

28.32

34.28

32.12

United Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															18.05	65.79	10.33	46.03	11.71

Competitive Comparison of United Therapeutics's FCF Margin %

For the Biotechnology subindustry, United Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where United Therapeutics's FCF Margin % falls into.

United Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

United Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	747.6	/	2327.5
	=	32.12 %

United Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	72	/	614.7
	=	11.71 %

United Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of United Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (United Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Executives

Paul A Mahon	officer: EVP & General Counsel
Nilda Mesa	director	C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey	director
Martine A Rothblatt	director, officer: Chief Executive Officer
Louis W Sullivan	director
Judy D. Olian	director	2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz	officer: President and COO	C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky	director
Raymond Dwek	director
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein	director	STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner	director	C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs	director, officer: President and COO
David Zaccardelli	officer: EVP & Chief Operating Officer	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069